

04 - References

References

Drug treatment of other psychiatric conditions CHAPTER 9 References

1. Winsper C, et al. The prevalence of personality disorders in the community: a global systematic review and meta-analysis. *Br J Psychiatry* 2020; 216:69–78.
2. Leichsenring F, et al. Borderline personality disorder: a review. *JAMA* 2023; 329:670–679.
3. Pascual JC, et al. Pharmacological management of borderline personality disorder and common comorbidities. *CNS Drugs* 2023; 37:489–497.
4. Riffer F, et al. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. *Int J Psychiatry Clin Pract* 2019; 23:178–188.
5. Paton C, et al. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. *J Clin Psychiatry* 2015; 76:e512–e518.
6. Storebø OJ, et al. Psychological therapies for people with borderline personality disorder. *Cochrane Database Syst Rev* 2020; 5:CD012955.
7. Setkowski K, et al. Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality disorder? A systematic review and network meta-analysis. *Psychol Med* 2023; 53:3261–3280.
8. National Institute for Clinical Excellence. Borderline personality disorder: recognition and management. Clinical Guideline [CG78]. 2009 (last checked April 2022, last accessed January 2024); <https://www.nice.org.uk/guidance/CG78>.
9. Del Casale A, et al. Current clinical psychopharmacology in borderline personality disorder. *Curr Neuropharmacol* 2021; 19:1760–1779.
10. Gartlehner G, et al. Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis. *CNS Drugs* 2021; 35:1053–1067.
11. Stoffers-Winterling JM, et al. Pharmacological interventions for people with borderline personality disorder. *Cochrane Database Syst Rev* 2022; 11:CD012956.
12. ClinicalTrials.gov. Seroquel extended release (XR) for the management of borderline personality disorder (BPD). NCT00880919. 2017; <https://clinicaltrials.gov/study/NCT00880919?tab=results>.
13. Black DW, et al. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 2014; 171:1174–1182.
14. Han J, et al. A systematic review of the role of clozapine for severe borderline personality disorder. *Psychopharmacology (Berl)* 2023; 240:2015–2031.

15. ClinicalTrials.gov. Caplyta in borderline personality disorder. NCT05356013. 2023; <https://clinicaltrials.gov/study/NCT05356013?cond=Borderline%20Personality%20Disorder&page=2&rank=11>.
16. ClinicalTrials.gov. Treating suicidal behavior and self-mutilation in people with borderline personality disorder. NCT00533117. 2024; <https://clinicaltrials.gov/ct2/show/results/NCT00533117>.
17. Bellino S, et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. *J Psychopharmacol* 2010; 24:333-339.
18. Markovitz PJ, et al. Venlafaxine in the treatment of borderline personality disorder. *Psychopharmacol Bull* 1995; 31:773-777.
19. Kutcher S, et al. The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. *J Psychiatry Neurosci* 1995; 20:113-118.
20. Lieslehto J, et al. Association of pharmacological treatments and real-world outcomes in borderline personality disorder. *Acta Psychiatr Scand* 2023; 147:603-613.
21. Essential Pharma Ltd. Summary of product characteristics. Camcolit 400mg prolonged release lithium carbonate. 2023; <https://www.medicines.org.uk/emc/product/10829/smpc>.
22. ClinicalTrials.gov. Preliminary trial of the effect of glucocorticoid receptor antagonist on borderline personality disorder (BPD). NCT01212588. 2019; <https://clinicaltrials.gov/ct2/show/NCT01212588>.
23. Fineberg SK, et al. A pilot randomized controlled trial of ketamine in borderline personality disorder. *Neuropsychopharmacology* 2023; 48:991-999.
24. Danayan K, et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. *Psychiatry Res* 2023; 323:115133.
25. Nandan NK, et al. 'Esketamine' in borderline personality disorder: a look beyond suicidality. *Cureus* 2022; 14:e24632.
26. Karaszewska DM, et al. Marine omega-3 fatty acid supplementation for borderline personality disorder: a meta-analysis. *J Clin Psychiatry* 2021; 82:20r13613.
27. Wollmer MA, et al. Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: a randomized controlled trial. *J Psychopharmacol* 2022; 36:159-169.
28. Links PS, et al. Prospective follow-up study of borderline personality disorder: prognosis, prediction of outcome, and axis II comorbidity. *Can J Psychiatry* 1998; 43:265-270.
29. Gardner DL, et al. Alprazolam-induced dyscontrol in borderline personality disorder. *Am J Psychiatry* 1985; 142:98-100.

Revision #1

Created 2026-01-04 20:17:25 UTC by Omar Ayman

Updated 2026-01-04 20:17:25 UTC by Omar Ayman